1. DOP56 Histologic disease activity correlates with endoscopic severity in patients with moderate to severe Crohn's Disease. (21st January 2022) Authors: Reinisch, W; De Hertogh, G; Protic, M; Chan, L S; Magro, F; Pollack, P; Feagan, B G; Harpaz, N; Pai, R Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i103 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DOP87 Association of histologic measurement with endoscopic outcomes after one year of treatment with mirikizumab in patients with moderate to severe Crohn's Disease. (21st January 2022) Authors: Magro, F; De Hertogh, G; Protic, M; Chan, L S; Pollack, P; Feagan, B G; Harpaz, N; Pai, R; Reinisch, W Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i129 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P-242International prospective multi-center clinical trial with adherence to surgical and pathological quality measures: Influence of body mass index (BMI) on outcome in colon cancer. (20th June 2018) Authors: Protic, M; Bilchik, A; Nissan, A; Knezevic, S Usaj; Kukic, B; Kresoja, M; Veljkovic, R; Zivojinov, M; Stojadinovic, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P312 Combination corticosteroids with, 5-aminosalicylic acid versus corticosteroids alone in the treatment of hospitalized patients with acute severe ulcerative colitis: A multi-center randomized controlled trial. (21st January 2022) Authors: Ben-Horin, S; Har-Noy, O; Katsanos, K H; Xavier, R; Chen, M H; Gao, X; Schwartz, D; Cheon, J H; Cesarini, M; Bojic, D; Protic, M; Theodoropoulou, A; Abu-Kaf, H; Engel, T; Tang, J; Veyrard, P; Lin, X; Mao, R; Christodoulou, D; Karmiris, K Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i337 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P395 Impact of mirikizumab therapy on histologic measures of intestinal inflammation in a Phase 2 study of patients with moderately to severely active Crohn's disease. (27th May 2021) Authors: Pai, R; De Hertogh, G; Reinisch, W; Harpaz, N; Feagan, B; Agada, N; Pollack, P; Chan, L S; Protic, M; Magro, F Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S404 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗